Literature DB >> 18413816

Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients.

Frank M Speetjens1, Peter J K Kuppen, Maro H Sandel, Anand G Menon, Danny Burg, Cornelis J H van de Velde, Rob A E M Tollenaar, Hans J G M de Bont, J Fred Nagelkerke.   

Abstract

PURPOSE: We isolated a subline (CC531M) from the CC531S rat colon carcinoma cell line, which grows and metastasizes much more rapidly than CC531S. We found, using RNA expression profiling, that one of the major changes in the CC531M cell line was a 5.8-fold reduction of the chemokine CXCL5. The purpose of this study was to determine the effect of CXCL5 expression on colorectal tumor growth and metastasis. EXPERIMENTAL
DESIGN: CC531 clones were generated with either knockdown or restored expression of CXCL5. These clones were inoculated in the liver of rats. In addition, in two independent cohorts of colorectal cancer patients, the level of CXCL5 expression was determined and associated to clinical variables.
RESULTS: Knockdown of CXCL5 expression in CC531S resulted in rapid tumor growth and increased number of metastasis, whereas restored expression of CXCL5 in CC531M resulted in a return of the "mild" tumor growth pattern of the parental cell line CC531S. In vitro, no difference was found in proliferation rate between clones with either high or low expression of CXCL5, suggesting that environmental interactions directed by CXCL5 determine tumor outgrowth. Finally, the importance of our findings was established for patients with colorectal cancer. We found that low expression of CXCL5 was significantly associated with poor prognosis for colorectal cancer patients. CXCL5 showed a trend (P = 0.05) for a positive correlation with intratumoral CD8(+) T-cell infiltration, suggesting a possible explanation for the observed poorer prognosis.
CONCLUSIONS: Our results show that CXCL5 is important in growth and development of colorectal cancer, implicating a future role in both cancer therapy and diagnosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413816     DOI: 10.1158/1078-0432.CCR-07-4045

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  29 in total

1.  CXCR4/CXCL12 expression profile is associated with tumor microenvironment and clinical outcome of liver metastases of colorectal cancer.

Authors:  Nozomu Sakai; Hiroyuki Yoshidome; Takashi Shida; Fumio Kimura; Hiroaki Shimizu; Masayuki Ohtsuka; Dan Takeuchi; Masahiro Sakakibara; Masaru Miyazaki
Journal:  Clin Exp Metastasis       Date:  2011-11-11       Impact factor: 5.150

2.  Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 pathways.

Authors:  Dong Cui; Yongfu Zhao; Jingchao Xu
Journal:  Cancer Biol Ther       Date:  2018-11-07       Impact factor: 4.742

3.  CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes.

Authors:  Oksana Kowalczuk; Tomasz Burzykowski; Wieslawa Ewa Niklinska; Miroslaw Kozlowski; Lech Chyczewski; Jacek Niklinski
Journal:  Tumour Biol       Date:  2014-02-06

4.  Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer.

Authors:  Aihua Li; Jonathan King; Aune Moro; Mark D Sugi; David W Dawson; Jeffrey Kaplan; Gang Li; Xuyang Lu; Robert M Strieter; Marie Burdick; Vay Liang W Go; Howard A Reber; Guido Eibl; O Joe Hines
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

5.  IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5(+) B- and T-cell trafficking to tumor-conditioned media.

Authors:  Erica Maria Pimenta; Saurav De; Ryan Weiss; Di Feng; Kelly Hall; Sarah Kilic; Gyan Bhanot; Shridar Ganesan; Sophia Ran; Betsy J Barnes
Journal:  Immunol Cell Biol       Date:  2014-12-23       Impact factor: 5.126

6.  Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis.

Authors:  M Tessema; D M Klinge; C M Yingling; K Do; L Van Neste; S A Belinsky
Journal:  Oncogene       Date:  2010-06-21       Impact factor: 9.867

7.  CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.

Authors:  Pierre Saintigny; Erminia Massarelli; Steven Lin; Young-Ho Ahn; Yulong Chen; Sangeeta Goswami; Baruch Erez; Michael S O'Reilly; Diane Liu; J Jack Lee; Li Zhang; Yuan Ping; Carmen Behrens; Luisa M Solis Soto; John V Heymach; Edward S Kim; Roy S Herbst; Scott M Lippman; Ignacio I Wistuba; Waun Ki Hong; Jonathan M Kurie; Ja Seok Koo
Journal:  Cancer Res       Date:  2012-11-30       Impact factor: 12.701

Review 8.  The role of chemokines in intestinal inflammation and cancer.

Authors:  Dingzhi Wang; Raymond N Dubois; Ann Richmond
Journal:  Curr Opin Pharmacol       Date:  2009-09-04       Impact factor: 5.547

9.  Interleukin-16 polymorphisms as new promising biomarkers for risk of gastric cancer.

Authors:  Seyed Mohammad Hossein Kashfi; Faegheh Behboudi Farahbakhsh; Ehsan Nazemalhosseini Mojarad; Kazem Mashayekhi; Pedram Azimzadeh; Sara Romani; Shaghayegh Derakhshani; Habib Malekpour; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Tumour Biol       Date:  2015-09-07

10.  CXCL5 as an autocrine or paracrine cytokine is associated with proliferation and migration of hepatoblastoma HepG2 cells.

Authors:  Yang Yang; Jie Hou; Mingliang Shao; Wei Zhang; Yaling Qi; Shengnan E; Shuqiu Wang; Hongyu Sui; Dexin Meng; Baixin Wang; Mingfu Wang; Yang Han; Yu Cao; Xiaoqing Huang; Yue Li; Pengxia Zhang; Weiqun Wang
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.